Narayan Prabhu - Reviva Pharmaceuticals Chief Officer
| RVPH Stock | USD 1.14 0.02 1.79% |
Insider
Narayan Prabhu is Chief Officer of Reviva Pharmaceuticals Holdings
| Age | 52 |
| Address | 10080 N. Wolfe Road, Cupertino, CA, United States, 95014 |
| Phone | 408-501-8881 |
| Web | https://www.revivapharma.com |
Latest Insider Transactions
Narayan Prabhu Latest Insider Activity
Tracking and analyzing the buying and selling activities of Narayan Prabhu against Reviva Pharmaceuticals stock is an integral part of due diligence when investing in Reviva Pharmaceuticals. Narayan Prabhu insider activity provides valuable insight into whether Reviva Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Reviva Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Reviva Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Narayan Prabhu over two months ago Acquisition by Narayan Prabhu of 96519 shares of Reviva Pharmaceuticals at 1.2 subject to Rule 16b-3 |
Reviva Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (2.3395) % which means that it has lost $2.3395 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.9506) %, meaning that it created substantial loss on money invested by shareholders. Reviva Pharmaceuticals' management efficiency ratios could be used to measure how well Reviva Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The Reviva Pharmaceuticals' current Return On Tangible Assets is estimated to increase to about (1.6 M). The Reviva Pharmaceuticals' current Return On Capital Employed is estimated to increase to about (5.8 M). As of now, Reviva Pharmaceuticals' Net Tangible Assets are increasing as compared to previous years. The Reviva Pharmaceuticals' current Other Assets is estimated to increase to about 467.6 K, while Total Current Assets are projected to decrease to under 15.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Samik MD | Cabaletta Bio | N/A | |
| Robert Renninger | Athira Pharma | 40 | |
| MBA MBA | Athira Pharma | 54 | |
| Michael Pine | Eyepoint Pharmaceuticals | 47 | |
| Brendan Teehan | ACADIA Pharmaceuticals | 55 | |
| MSPH MD | ACADIA Pharmaceuticals | 67 | |
| Isabelle Lefebvre | Eyepoint Pharmaceuticals | N/A | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| John CPA | Sellas Life Sciences | 39 | |
| Julie Rathbun | Athira Pharma | N/A | |
| James Kihara | ACADIA Pharmaceuticals | 43 | |
| Anup MBA | Cabaletta Bio | 46 | |
| MPA MD | Unicycive Therapeutics | 51 | |
| Kishor Bhatia | Lantern Pharma | 69 | |
| ScD MD | Sellas Life Sciences | 48 | |
| Aimee MD | Cabaletta Bio | N/A | |
| Steven Almo | Cue Biopharma | 63 | |
| Martha OConnor | Cabaletta Bio | N/A | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| TaiWei Ho | In8bio Inc | 47 | |
| Steven MD | Cabaletta Bio | 63 | |
Management Performance
| Return On Equity | -17.95 | ||||
| Return On Asset | -2.34 |
Reviva Pharmaceuticals Leadership Team
Elected by the shareholders, the Reviva Pharmaceuticals' board of directors comprises two types of representatives: Reviva Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Reviva. The board's role is to monitor Reviva Pharmaceuticals' management team and ensure that shareholders' interests are well served. Reviva Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Reviva Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Narayan Prabhu, Chief Officer | ||
| Laxminarayan Bhat, CEO, Founder |
Reviva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Reviva Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -17.95 | ||||
| Return On Asset | -2.34 | ||||
| Current Valuation | 32.65 M | ||||
| Shares Outstanding | 33.44 M | ||||
| Shares Owned By Insiders | 14.78 % | ||||
| Shares Owned By Institutions | 30.06 % | ||||
| Number Of Shares Shorted | 6.43 M | ||||
| Price To Book | 8.35 X | ||||
| EBITDA | (10.1 M) | ||||
| Net Income | (39.26 M) |
Currently Active Assets on Macroaxis
When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.10) | Return On Assets (2.34) | Return On Equity (17.95) |
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.